National Institute on Drug Abuse

US-Cannabis Market is to grow by USD 46.90 billion between 2022 - 2027 | Rising millennial population Drive Demand for the market - Technavio

Retrieved on: 
Thursday, November 9, 2023
Aurora, Cannabis, Timeline of cannabis laws in the United States, Food, CBD, Millennials, ROW, Research, Geography, Software, Research report, Medical cannabis, Growth, Medical Marijuana, Inc., NIDA, Jazz Pharmaceuticals, MM, USD, National Institute on Drug Abuse, Compound annual growth rate, Drug, Retail

Millennials, the largest US population, are driving this growth with their enthusiasm for diverse cannabis products, particularly for recreational use.

Key Points: 
  • Millennials, the largest US population, are driving this growth with their enthusiasm for diverse cannabis products, particularly for recreational use.
  • Growth Prospects of the US Cannabis Market in Emerging Markets include:
    The emphasis on the medical potential of cannabis is propelling a surge in research and development.
  • As millennials drive demand, medical research advances and innovative trends emerge, the market is positioned for unparalleled expansion.
  • Cannabis-infused Edible Products Market: The global cannabis-infused edible products market share is expected to increase by USD 5,638.94 million from 2022 to 2027, and the market's growth momentum will accelerate at a CAGR of 19.32%.

BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)

Retrieved on: 
Monday, November 6, 2023
Post-traumatic stress disorder, FDA, Yale School of Medicine, Opioid use disorder, Standard of care, Intelligence, Government, Public Health Service Act, White House, Dexmedetomidine, Opioid epidemic, BID, Federal Food, Drug, and Cosmetic Act, Federation, Addiction, Xylazine, Psychiatry, COWS, Recreational drug use in Kenya, Locus coeruleus, Pharmacokinetics, OUD, National Institute on Drug Abuse, NIDA, Columbia University, NIH, Safety, Public, American Journal, Minneapolis Veterans Affairs Health Care System, Therapy, Office of Inspector General, U.S. Department of Health and Human Services, Patient, Fentanyl, Bangladesh Technical Education Board, RTI International, United States Public Health Service, Pharmaceutical industry, Neuroscience

NEW HAVEN, Conn., Nov. 06, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced an update on the National Institute on Drug Abuse (NIDA)-funded trial evaluating BXCL501 (sublingual dexmedetomidine) as a potential treatment for opioid use disorder (OUD).

Key Points: 
  • NIDA has requested Columbia University, the trial coordinator, to add a fourth site to target trial completion in 2024.
  • After this time, BioXcel Therapeutics plans to seek FDA feedback on potential registrational paths.
  • “With BXCL501, we are excited about the potential to treat patients who are physically dependent on illicit and prescription opioids.
  • In addition to OUD as an indication, BioXcel Therapeutics has been awarded key opportunities for the development of BXCL501 in post-traumatic stress disorder and alcohol use disorder.

CARI Health Awarded NIH Grant of up to $2.8M to Advance Remote Medication Monitoring

Retrieved on: 
Thursday, October 19, 2023
Wearables, Mobile Technology, Technology, Medical Devices, Health Technology, Biometrics, Biotechnology, Managed Care, General Health, Pharmaceutical, Health, Digital, Research, Opioid use disorder, Marianne Schmidl, SDAC, Global Entrepreneur, UCSD, Medtech, Conference, Methadone, CARI, National Institute on Drug Abuse, NIDA, University, Device, NIH, Investment, Patient, Bangladesh Technical Education Board, Pharmaceutical industry

Digital health startup CARI Health was awarded an SBIR Fast Track grant from the National Institute on Drug Abuse (NIDA), an agency of the National Institutes of Health (NIH), to help it bring the world’s first wearable medication monitor to market.

Key Points: 
  • Digital health startup CARI Health was awarded an SBIR Fast Track grant from the National Institute on Drug Abuse (NIDA), an agency of the National Institutes of Health (NIH), to help it bring the world’s first wearable medication monitor to market.
  • CARI Health is eligible for up to $2.8M over three years as project milestones are successfully completed within Phase I and Phase II portions of the grant.
  • The award funding will go toward supporting product development and conducting human clinical studies for CARI Health’s wearable remote medication monitoring device .
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Cessation Therapeutics Awarded $14.8 Million Grant from the National Institute of Drug Abuse to Develop Novel Formulation of Anti-Fentanyl Monoclonal Antibody

Retrieved on: 
Wednesday, October 18, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Mass General Brigham, Buprenorphine, Opioid use disorder, Harvard Medical School, IND, Drug, McLean Hospital, Assistant, U.S. government and smoking cessation, Psychiatry, Doctor of Philosophy, Naltrexone, Methadone, Development, OUD, National Institute on Drug Abuse, NIDA, Immunoglobulin G, Research and development, Blood, Brain, Mass, Therapy, Fentanyl, Bangladesh Technical Education Board, Pharmaceutical industry

The new grant (UG3DA058544) is part of a multi-year award expected to total $14.8 million given to Cessation and McLean Hospital, a member of Mass General Brigham.

Key Points: 
  • The new grant (UG3DA058544) is part of a multi-year award expected to total $14.8 million given to Cessation and McLean Hospital, a member of Mass General Brigham.
  • Through different delivery methods, the platform can be optimized to potentially protect against overdose, reverse overdose, and treat fentanyl-related opioid use disorder (OUD).
  • “We are grateful to NIDA for their continued support of Cessation’s anti-fentanyl development programs,” said Andy Barrett, PhD, Chief Scientific Officer at Cessation Therapeutics.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Webinar to Commemorate Statewide Knock Out Opioid Abuse Day

Retrieved on: 
Monday, October 2, 2023
National Institute on Drug Abuse, Drug, Communication, Advertising, Drug Enforcement Administration, Partnership, New Jersey Division of Consumer Affairs, Addiction, Human services, United States Department of Health and Human Services, COVID-19, Policy, Consumer protection, New Jersey Department of Health, United States drug overdose death rates and totals over time, Heller School for Social Policy and Management, Heroin, Bangladesh Technical Education Board, Government, Organization, Social policy, NIDA, Prohibition, New Jersey State Police, Fentanyl, A True Tale of Robin Hood, Pharmaceutical industry

The webinar, “Knock Out Opioid Abuse Day: An Update from NIDA,” will be held at 11 a.m. Friday, October 6 in recognition of the eighth annual Knock Out Opioid Abuse Day in New Jersey.

Key Points: 
  • The webinar, “Knock Out Opioid Abuse Day: An Update from NIDA,” will be held at 11 a.m. Friday, October 6 in recognition of the eighth annual Knock Out Opioid Abuse Day in New Jersey.
  • “Knock Out Opioid Abuse Day is an important day in New Jersey,” said PDFNJ Executive Director Angelo Valente.
  • This webinar will present a tremendous opportunity for concerned citizens to increase their understanding of the issue and make a difference in their community.”
    The webinar will be the ninth in the 2023 Knock Out Opioid Abuse Day Learning Series.
  • To learn more about Knock Out Opioid Abuse Day and for a schedule of webinars, please visit knockoutday.drugfreenj.org .

Leading Epidemiologist Wendy Cheng Joins BRG's Healthcare Practice as Managing Director

Retrieved on: 
Wednesday, September 27, 2023
Columbia University, Pharmacy, BRG, Columbia University Mailman School of Public Health, Health care, Prognosis, Research, Doctor of Philosophy, EMA, Public health, Machine learning, National Institute on Drug Abuse, European Medicines Agency, Iterative method, FDA, MPH, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Epidemiology, Berkeley Research Group, Food, Safety, Medical device, Pharmaceutical industry

BOSTON, Sept. 27, 2023 /PRNewswire/ -- Global expert services and consulting firm Berkeley Research Group (BRG) announced today that epidemiology expert Wendy Cheng has joined the firm's Boston office as a managing director in its Healthcare practice.

Key Points: 
  • Dr. Cheng also provides expert support and testimony in disputes that require the analysis of clinical data.
  • Most recently, Dr. Cheng was a vice president at a leading healthcare consulting firm, where she spent more than a decade advising pharmaceutical companies on data analytics for product development, regulatory approval and market adoption.
  • "Wendy's knowledge of advanced epidemiologic research methods and tools such as machine learning is at the leading edge in the field," said Edward Buthusiem , a managing director in BRG's Health Analytics practice.
  • Dr. Cheng commented, "I am excited to be a part of BRG's Healthcare practice and to join a team of leading experts and renowned researchers in the field.

Progress in the Battle Against Opioid Epidemic: New Jersey Records Decrease in Overdoses

Retrieved on: 
Monday, September 25, 2023
White House, Horizon blue, Communication, Xylazine, Advertising, Partnership, Education, Office of National Drug Control Policy, Parent, Horizon Blue Cross Blue Shield of New Jersey, Bangladesh Technical Education Board, RX, Government, CDC, Organization, Death, Dentist, Drug, Patient, Risk, Korea Disease Control and Prevention Agency, NIDA, National Institute on Drug Abuse, Prohibition, Policy, Legislation, Pharmaceutical industry, Nursing

New Jersey government and advocacy community have worked together to save lives from the opioid crisis, including the designation by the legislature and Gov.

Key Points: 
  • New Jersey government and advocacy community have worked together to save lives from the opioid crisis, including the designation by the legislature and Gov.
  • Murphy of October 6, 2023 as Knock Out Opioid Abuse Day – a day of awareness and education on the opioid epidemic coordinated by PDFNJ – and, the Knock Out Opioid Abuse Day Learning Series.
  • PDFNJ is also working with Horizon Blue Cross Blue Shield of New Jersey to educate student-athletes on the risks of opioids.
  • Since its inception, the Partnership has garnered 217 advertising and public relations awards from national, regional and statewide media organizations.

Biobot Analytics Awarded NIDA Funding for Nationwide Wastewater-Based Monitoring Program for High Risk Substances and Others Associated with Health Risks

Retrieved on: 
Thursday, September 21, 2023
Xylazine, Organizational founder, Prevalence, Methamphetamine, Naloxone, Public, SBIR, America's Essential Hospitals, United States drug overdose death rates and totals over time, Phase II, Bangladesh Technical Education Board, Cocaine, National Institute on Drug Abuse, Drug, NIDA, Research, Epidemiology, Fentanyl, Support, Pharmaceutical industry, Medical device

CAMBRIDGE, Mass., Sept. 21, 2023 /PRNewswire/ -- Biobot Analytics, a global leader in wastewater epidemiology, was awarded a Phase III Small Business Innovation Research (SBIR) contract from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health to conduct anonymous, population-level wastewater-based monitoring on drugs and overdose reversal agents. This program is a groundbreaking initiative aimed at evaluating the distribution of substance use and misuse on a national level.

Key Points: 
  • This program is a groundbreaking initiative aimed at evaluating the distribution of substance use and misuse on a national level.
  • Biobot's work is a vital step forward in the country's collective efforts to address substance use and misuse.
  • "Biobot Analytics was originally founded in 2017 to help communities address the opioid epidemic through wastewater monitoring," said Dr. Mariana Matus, CEO and Cofounder of Biobot Analytics.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting

Retrieved on: 
Monday, September 11, 2023
Smoker, Society, Nicotine, Week, Public, Research, Bangladesh Technical Education Board, Trial of the century, Harvard Medical School, Insomnia, National Institute on Drug Abuse, University of California, San Francisco Fetal Treatment Center, Annual general meeting, Nausea, FDA, Massachusetts General Hospital, Smoking, Headache, NIH, Herbal cigarette, Tobacco, Medicine

The positive topline results from the ORCA-V1 trial, announced earlier this year, will be presented, as well as additional findings.

Key Points: 
  • The positive topline results from the ORCA-V1 trial, announced earlier this year, will be presented, as well as additional findings.
  • Additional analyses showed that vaping abstinence with cytisinicline treatment started by the second week of treatment, with the odds of vaping cessation improving throughout the 12-week treatment period.
  • During the Week 12-16 follow-up period, subjects treated with cytisinicline continued to demonstrate 2.0 times higher odds of vaping cessation compared to placebo.
  • The content is the sole responsibility of the authors and does not necessarily represent the official views of the NIH.

The Dallas Morning News Launches Transformative Series Examining Fentanyl’s Deadly Grip on North Texas

Retrieved on: 
Thursday, September 7, 2023
News, National Institute on Drug Abuse, University of Texas Health Science Center at San Antonio, Naloxone, Human services, DallasNews Corporation, Hope, Centers for Disease Control and Prevention, The Dallas Morning News, Heroin, Texas Health and Human Services Commission, Organization, School, Morphine, Text, Knowledge, Dallas, Partnership to End Addiction, Fentanyl, Pharmaceutical industry, DALLAS

DALLAS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- DallasNews Corporation (Nasdaq: DALN) -

Key Points: 
  • The potent synthetic opioid has been responsible for the overdose deaths of over 1,100 North Texans since 2021.
  • More than two dozen News staffers spent months researching, reporting, writing, editing, photographing and designing a wide-ranging package about the deadly drug.
  • “Deadly Fake: 30 Days Inside Fentanyl’s Grip on North Texas,” tells in heart-breaking and stark detail the rapidly growing crisis unfolding across the nation and at home.
  • North Texas Behavioral Health Authority: 24-hour crisis hotline at 1-866-260-8000 or ntbha.org .